<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04680338</url>
  </required_header>
  <id_info>
    <org_study_id>NL64860.042.18</org_study_id>
    <nct_id>NCT04680338</nct_id>
  </id_info>
  <brief_title>Early Detection of Silent Myocardial Ischemia</brief_title>
  <acronym>EarlySynergy</acronym>
  <official_title>Early Detection of Silent Myocardial Ischemia and Cardiac Dysfunction in Asymptomatic Individuals With Increased Coronary Artery Calcium Scores</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pim van der Harst</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early-Synergy investigates a diagnostic imaging approach in asymptomatic individuals from the&#xD;
      general population for early detection of silent myocardial ischemia and cardiac dysfunction.&#xD;
      The diagnostic imaging approach consists of cardiac computed tomography for coronary artery&#xD;
      calcium scoring (CT-CAC) and cardiac magnetic resonance (CMR) stress perfusion imaging.&#xD;
      Early-Synergy investigates the effect of early detection of silent myocardial ischemia and&#xD;
      cardiac dysfunction by CMR in asymptomatic individuals with increased CAC. In addition, the&#xD;
      diagnostic yield of CMR for early detection of silent myocardial ischemia and cardiac&#xD;
      dysfunction is investigated. Asymptomatic individuals at increased risk (CAC ≥ 300) are&#xD;
      therefore randomized 1:1 to either CMR stress perfusion imaging or a control group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early-Synergy is a prospective multi-center study performed in the Netherlands. Potential&#xD;
      candidates for participation in Early-Synergy have had CT-CAC scanning as part of&#xD;
      participation in two ongoing population-based studies (ROBINSCA and ImaLife) and had CAC&#xD;
      ≥300.&#xD;
&#xD;
      Participants are randomized in a 1:1 fashion to (1.) CMR stress perfusion imaging with&#xD;
      feedback of clinically actionable findings or (2.) control group.&#xD;
&#xD;
      In the CMR group, feedback on CMR stress perfusion imaging is provided to the participant and&#xD;
      general practitioner only in case of CMR findings that require further management based on&#xD;
      current clinical guidelines. Participants in the control group will not receive stress CMR&#xD;
      perfusion imaging but will be followed in time to evaluate the clinical presentation of the&#xD;
      natural course of coronary atherosclerosis.&#xD;
&#xD;
      Follow-up will be performed up to 5 years in both groups by sending questionnaires and&#xD;
      collecting medical information from health care providers and registries. Additionally, blood&#xD;
      is drawn from participants in the CMR group during the hospital visit for CMR scanning and is&#xD;
      stored to allow evaluation of cardiac blood markers as predictors of CMR findings.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 27, 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of major adverse cardiac events</measure>
    <time_frame>1 year</time_frame>
    <description>Cardiovascular death, non-fatal myocardial infarction or hospitalization for unstable angina, heart failure or resuscitated cardiac arrest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of major adverse cardiac events</measure>
    <time_frame>2.5 years</time_frame>
    <description>Cardiovascular death, non-fatal myocardial infarction or hospitalization for unstable angina, heart failure or resuscitated cardiac arrest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of major adverse cardiac events</measure>
    <time_frame>5 years</time_frame>
    <description>Cardiovascular death, non-fatal myocardial infarction or hospitalization for unstable angina, heart failure or resuscitated cardiac arrest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic yield of CMR stress perfusion imaging</measure>
    <time_frame>Baseline</time_frame>
    <description>Prevalence and extent of silent myocardial ischemia and cardiac dysfunction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of individual components of primary outcome 1</measure>
    <time_frame>1 year</time_frame>
    <description>Cardiovascular death, non-fatal myocardial infarction or hospitalization for unstable angina, heart failure or resuscitated cardiac arrest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of individual components of primary outcome 1</measure>
    <time_frame>2.5 years</time_frame>
    <description>Cardiovascular death, non-fatal myocardial infarction or hospitalization for unstable angina, heart failure or resuscitated cardiac arrest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of individual components of primary outcome 1</measure>
    <time_frame>5 years</time_frame>
    <description>Cardiovascular death, non-fatal myocardial infarction or hospitalization for unstable angina, heart failure or resuscitated cardiac arrest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality rate</measure>
    <time_frame>1 year</time_frame>
    <description>Death from any disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality rate</measure>
    <time_frame>2.5 years</time_frame>
    <description>Death from any disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality rate</measure>
    <time_frame>5 years</time_frame>
    <description>Death from any disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of invasive cardiovascular procedures</measure>
    <time_frame>1 year</time_frame>
    <description>percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) surgery, invasive coronary angiography (ICA) and other invasive cardiovascular procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of invasive cardiovascular procedures</measure>
    <time_frame>2.5 years</time_frame>
    <description>percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) surgery, invasive coronary angiography (ICA) and other invasive cardiovascular procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of invasive cardiovascular procedures</measure>
    <time_frame>5 years</time_frame>
    <description>percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) surgery, invasive coronary angiography (ICA) and other invasive cardiovascular procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospitalization for cardiovascular disease</measure>
    <time_frame>1, 2.5, 5 years</time_frame>
    <description>Hospitalization for cardiovascular disease (e.g. stroke, peripheral vascular disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospitalization for cardiovascular disease</measure>
    <time_frame>1 year</time_frame>
    <description>Hospitalization for cardiovascular disease (e.g. stroke, peripheral vascular disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospitalization for cardiovascular disease</measure>
    <time_frame>2.5 years</time_frame>
    <description>Hospitalization for cardiovascular disease (e.g. stroke, peripheral vascular disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-invasive cardiac imaging procedures</measure>
    <time_frame>5 years</time_frame>
    <description>Rate of non-invasive cardiac imaging procedures (e.g., myocardial stress perfusion imaing, echocardiography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of medical therapy initiation</measure>
    <time_frame>1 year</time_frame>
    <description>Initiation of preventive or cardio-active medication (e.g., ACE-inhibiters, statins, calcium antagonists, beta-blockers etc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of medical therapy initiation</measure>
    <time_frame>2.5 years</time_frame>
    <description>Initiation of preventive or cardio-active medication (e.g., ACE-inhibiters, statins, calcium antagonists, beta-blockers etc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of medical therapy initiation</measure>
    <time_frame>5 years</time_frame>
    <description>Initiation of preventive or cardio-active medication (e.g., ACE-inhibiters, statins, calcium antagonists, beta-blockers etc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as reflected by EQ-5D-5S score</measure>
    <time_frame>1 year</time_frame>
    <description>Quality of life as assessed by EQ-5D-5S questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as reflected by EQ-5D-5S score</measure>
    <time_frame>2.5 years</time_frame>
    <description>Quality of life as assessed by EQ-5D-5S questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as reflected by EQ-5D-5S score</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of life as assessed by EQ-5D-5S questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as reflected by HeartQoL score</measure>
    <time_frame>1 year</time_frame>
    <description>Quality of life as assessed by HeartQoL questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as reflected by HeartQoL score</measure>
    <time_frame>2.5 years</time_frame>
    <description>Quality of life as assessed by HeartQoL questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as reflected by HeartQoL score</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of life as assessed by HeartQoL questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>1 year</time_frame>
    <description>Cost-effectiveness of CMR stress perfusion imaging compared to control group</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>2.5 years</time_frame>
    <description>Cost-effectiveness of CMR stress perfusion imaging compared to control group</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>5 years</time_frame>
    <description>Cost-effectiveness of CMR stress perfusion imaging compared to control group</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Silent Myocardial Ischemia</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Cardiac magnetic resonance imaging</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cardiac magnetic resonance (CMR) stress perfusion imaging with feedback of clinically actionable findings</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention, following the natural course of coronary atherosclerosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CMR stress perfusion imaging</intervention_name>
    <description>CMR stress perfusion imaging with feedback of clinically actionable findings to general practitioner and participant</description>
    <arm_group_label>Cardiac magnetic resonance imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participation in ROBINSCA or ImaLife study&#xD;
&#xD;
          -  CT-CAC ≥300&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of ischemic heart disease or other cardiac disease (myocardial infarction,&#xD;
             sudden cardiac arrest, heart failure, cardiomyopathy, congenital cardiac disease,&#xD;
             percutaneous coronary intervention, coronary artery bypass grafting surgery, valvular&#xD;
             surgery, other major cardiac surgery (e.g. cardiac transplantation) and/or previous&#xD;
             invasive coronary angiography or catheter ablation)&#xD;
&#xD;
          -  Contra-indication for stress CMR perfusion imaging (claustrophobia, CMR incompatible&#xD;
             device (e.g., Implantable Cardioverter Defibrillator/pacemaker), contrast agent or&#xD;
             vasodilator intolerance, contra-indications for adenosine or regadenoson (e.g. 2nd/3rd&#xD;
             degree atrioventricular block, severe hypotension) and/or weight &gt; 125 kg)&#xD;
&#xD;
          -  Severe comorbidity and/or a life expectancy of less than 1 year&#xD;
&#xD;
          -  Unable to provide written informed consent&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pim van der Harst, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Xia C, Rook M, Pelgrim GJ, Sidorenkov G, Wisselink HJ, van Bolhuis JN, van Ooijen PMA, Guo J, Oudkerk M, Groen H, van den Berge M, van der Harst P, Dijkstra H, Vonder M, Heuvelmans MA, Dorrius MD, De Deyn PP, de Bock GH, Dotinga A, Vliegenthart R. Early imaging biomarkers of lung cancer, COPD and coronary artery disease in the general population: rationale and design of the ImaLife (Imaging in Lifelines) Study. Eur J Epidemiol. 2020 Jan;35(1):75-86. doi: 10.1007/s10654-019-00519-0. Epub 2019 Apr 23.</citation>
    <PMID>31016436</PMID>
  </reference>
  <reference>
    <citation>Vonder M, van der Aalst CM, Vliegenthart R, van Ooijen PMA, Kuijpers D, Gratama JW, de Koning HJ, Oudkerk M. Coronary Artery Calcium Imaging in the ROBINSCA Trial: Rationale, Design, and Technical Background. Acad Radiol. 2018 Jan;25(1):118-128. doi: 10.1016/j.acra.2017.07.010. Epub 2017 Aug 23. Review.</citation>
    <PMID>28843465</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Pim van der Harst</investigator_full_name>
    <investigator_title>Clinical professor, Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data management plan in progress</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>In accordance with legal period for study data storage</ipd_time_frame>
    <ipd_access_criteria>In correspondence with the principal investigator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

